EOLS · Evolus, Inc.
$6.15
-0.08 (-1.21%)
At close · Jul 29
Market Cap
$409.62M
Shares
65.85M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$297.18M
+11.6%
FY2025
Net Income
-$51.64M
-2.4%
FY2025
Gross Margin
66.33%
-2.1pp
FY2025
Operating Margin
-10.99%
+1.9pp
FY2025
Diluted EPS
-$0.80
+1.2%
FY2025
Operating Cash Flow
-$42.27M
-134.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2028 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $700M | $327M – $337M | $301.79M | $297.18MG | $266.27M | $202.09M | $148.62M | $99.67M | $56.54M | $34.93M | — | |
| — | — | $102.44M | $100.07M | $83.97M | $61.56M | $55.89M | $43.53M | $18.3M | $8.01M | — | |
| — | — | $199.35M | $197.11M | $182.3M | — | — | — | — | $26.91M | — | |
| — | — | — | 66.33% | 68.46% | — | — | — | — | 77.05% | — | |
| — | — | $9.6M | $9.58M | $9.17M | $6.56M | $4.74M | $2.06M | $1.72M | $3.97M | $6.49M | |
| — | — | $43.2M | — | — | — | — | — | — | — | $29.15M | |
| — | — | $216.13M | $220.79M | $198.03M | $164.94M | $141.84M | $112.07M | $98.19M | $113.59M | — | |
| — | — | $6.89M | $6.27M | $4.1M | $4.07M | $3.35M | $5.31M | $3.64M | $3.85M | — | |
| — | — | $8.29M | $7.51M | $5.3M | $5.13M | $3.72M | $5.62M | $7.03M | $4.13M | $9000 | |
| — | — | — | $1.44M | — | — | — | $0 | $2.96M | — | — | |
| — | — | $98.34M | — | — | — | — | — | — | $125.86M | $46.14M | |
| — | — | $223.69M | $229.77M | $216.72M | $251.32M | $213.95M | $144.08M | $209.61M | — | — | |
| — | — | -$24.34M | -$32.66M | -$34.41M | -$49.23M | -$65.33M | -$44.41M | -$153.07M | -$98.95M | -$46.14M | |
| — | — | — | -10.99% | -12.92% | -24.36% | -43.96% | -44.55% | -270.73% | -283.31% | — | |
| — | — | -$16.05M | -$25.16M | -$29.11M | -$44.1M | -$61.61M | -$38.78M | -$146.04M | -$94.82M | -$46.13M | |
| — | — | $19.25M | $19.69M | $18.74M | $13.83M | $9.1M | — | — | — | $863K | |
| — | — | — | — | — | — | — | — | — | — | $203K | |
| — | — | -$476K | -$539K | $127K | $696K | -$9000 | -$1.4M | -$10.5M | -$7.95M | — | |
| — | — | -$42.56M | -$50.96M | -$49.76M | -$61.51M | -$74.32M | -$46.77M | -$162.94M | -$105.06M | -$46.8M | |
| — | — | $861K | $677K | $664K | $176K | $95K | $42K | $77K | -$15.03M | $65K | |
| — | — | -$43.42M | -$51.64M | -$50.42M | -$61.69M | -$74.41M | -$46.81M | -$163.01M | -$90.03M | -$46.87M | |
| — | — | — | -17.38% | -18.94% | -30.52% | -50.07% | -46.96% | -288.31% | -257.79% | — | |
| — | — | -$42.86M | -$50.89M | -$50.9M | -$61.78M | -$74.75M | -$46.81M | -$163.02M | -$90.03M | -$46.87M | |
| USD/shares | — | — | — | -$0.80 | -$0.81 | -$1.08 | -$1.33 | -$0.94 | — | — | — |
| USD/shares | — | — | — | -$0.80 | -$0.81 | -$1.08 | -$1.33 | -$0.94 | — | — | — |
| shares | — | — | — | 64.47M | 62.02M | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.4M |
| shares | — | — | — | 64.47M | 62.02M | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.4M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.00×
EV/EBIT
—
Peer median 34.20×
P/E (TTM)
—
Peer median 15.54×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $297,176,000 | $266,274,000 | $202,085,000 | $148,616,000 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| United States | $253,159,000 | $195,424,000 | $146,150,000 | — | — | — |
| Non Us | $13,115,000 | $6,661,000 | $2,466,000 | — | — | — |
| Canada | — | — | — | $702,000 | $738,000 | $688,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $294,956,000 | $264,306,000 | $199,721,000 | $146,592,000 | $98,971,000 | $55,802,000 | $34,237,000 |
| Service | $2,220,000 | $1,968,000 | $2,364,000 | $2,024,000 | $702,000 | $738,000 | — |
Key facts
CIK
1570562
CUSIP
30052C107
13F (30d)
23 filings
23 filers
Visit website
Investor relations